Abstract:Editorial Office Translational Cancer Research Submitted Nov 20, 2023. Accepted for publication Jun 12, 2024. Published online Aug 27, 2024. doi: 10.21037/tcr-2024-2 Erratum to: Transl Cancer Res 2023;12:1372-5. In the May 2023 issue of Translational Cancer Research , the paper titled "Erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression" (Transl Cancer Res 2023;12(5):1372-1375. doi: 10.21037/tcr-23-674) (1), was published for correction of Figure 1C and Figure 5C in the article (2) published earlier. However, there are still some errors found in the aforementioned Figures 1C , 5C as well as in Figure 4C , while the figure legends remain intact. The Figure 1C should be corrected as: The Figure 4C should be corrected as: The Figure 5C should be corrected as: The authors confirmed that these corrections do not change the description or original conclusions of the paper and sincerely apologize for any inconvenience caused by these mistakes. Click here to view the updated version of the article. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Correction: Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma

[Corrigendum] Linc00961 Inhibits the Proliferation and Invasion of Skin Melanoma by Targeting the Mir‑367/pten Axis.

Paradoxical Role for Wild-Type P53 in Driving Therapy Resistance in Melanoma

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.

Correction: Wang et al. TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis. Biology 2022, 11, 141

Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

Correction to: Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

Corrigendum: LNMAT1 Promotes Invasion-Metastasis Cascade in Malignant Melanoma by Epigenetically Suppressing CADM1 Expression

Activation of the PI3K/Akt/mTOR/p70S6K Pathway is Involved in S100A4-Induced Viability and Migration in Colorectal Cancer Cells: Erratum

Correction to: The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis

Erratum to erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression

Restoring the Tumour Suppressive Function of P53 As a Parallel Strategy in Melanoma Therapy

Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy.

[Corrigendum] A Regulation Loop Between Nrf1α and MRTF‑A Controls Migration and Invasion in MDA‑MB‑231 Breast Cancer Cells.

Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512

Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Correction To: RIP1 Protects Melanoma Cells from Apoptosis Induced by BRAF/MEK Inhibitors.

Correction: Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

[Corrigendum] miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer